Comments
Loading...

Day One Biopharmaceutical Analyst Ratings

DAWNNASDAQ
Logo brought to you by Benzinga Data
$7.93
0.314.07%
At close: -
$7.93
0.000.00%
After Hours: May 2, 4:00 PM EDT
Q1 2025 earnings tomorrow on Tue May 6th after the market close
Conference call scheduled tomorrow at 16:30 PM Click to view the webcast
Consensus Rating1
Buy
Highest Price Target1
$40.00
Lowest Price Target1
$25.00
Consensus Price Target1
$33.33

Day One Biopharmaceutical Analyst Ratings and Price Targets | NASDAQ:DAWN | Benzinga

Day One Biopharmaceuticals Inc has a consensus price target of $33.33 based on the ratings of 10 analysts. The high is $40 issued by Piper Sandler on July 8, 2024. The low is $25 issued by B of A Securities on January 7, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Goldman Sachs, and JP Morgan on April 3, 2025, March 25, 2025, and March 5, 2025, respectively. With an average price target of $32.33 between HC Wainwright & Co., Goldman Sachs, and JP Morgan, there's an implied 307.73% upside for Day One Biopharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
2
Jan
4
Feb
2
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Goldman Sachs
JP Morgan
Wedbush
Needham

1calculated from analyst ratings

Analyst Ratings for Day One Biopharmaceutical

Buy NowGet Alert
04/03/2025Buy Now353.97%HC Wainwright & Co.
Andres Maldonado45%
$36 → $36ReiteratesBuy → BuyGet Alert
03/25/2025Buy Now240.48%Goldman Sachs
Andrea Tan40%
$39 → $27MaintainsBuyGet Alert
03/05/2025Buy Now328.75%JP Morgan
Anupam Rama59%
$39 → $34MaintainsOverweightGet Alert
02/26/2025Buy Now303.53%Wedbush
Robert Driscoll45%
$32 → $32ReiteratesOutperform → OutperformGet Alert
02/26/2025Buy Now353.97%HC Wainwright & Co.
Andres Maldonado45%
$40 → $36MaintainsBuyGet Alert
02/26/2025Buy Now303.53%Needham
Ami Fadia54%
$32 → $32ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now442.24%Goldman Sachs
Andrea Tan40%
$48 → $43MaintainsBuyGet Alert
01/13/2025Buy Now316.14%Needham
Ami Fadia54%
$33 → $33ReiteratesBuy → BuyGet Alert
01/07/2025Buy Now215.26%B of A Securities
Alec Stranahan33%
$28 → $25MaintainsBuyGet Alert
12/17/2024Buy Now328.75%Jones Trading—$39 → $34MaintainsBuyGet Alert
10/31/2024Buy Now404.41%HC Wainwright & Co.
Andres Maldonado45%
$40 → $40ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now316.14%Needham
Ami Fadia54%
$33 → $33ReiteratesBuy → BuyGet Alert
10/09/2024Buy Now316.14%Needham
Ami Fadia54%
$32 → $33MaintainsBuyGet Alert
08/06/2024Buy Now353.97%JP Morgan
Anupam Rama59%
$38 → $36MaintainsOverweightGet Alert
08/01/2024Buy Now404.41%HC Wainwright & Co.
Andres Maldonado45%
$40 → $40ReiteratesBuy → BuyGet Alert
08/01/2024Buy Now202.65%B of A Securities
Alec Stranahan33%
$11 → $24UpgradeUnderperform → BuyGet Alert
07/31/2024Buy Now303.53%Needham
Ami Fadia54%
$33 → $32MaintainsBuyGet Alert
07/30/2024Buy Now316.14%Needham
Ami Fadia54%
$33 → $33ReiteratesBuy → BuyGet Alert
07/26/2024Buy Now404.41%HC Wainwright & Co.
Andres Maldonado45%
$40 → $40ReiteratesBuy → BuyGet Alert
07/08/2024Buy Now404.41%Piper Sandler
Joseph Catanzaro43%
$40 → $40MaintainsOverweightGet Alert
06/20/2024Buy Now404.41%HC Wainwright & Co.
Andres Maldonado45%
$40 → $40ReiteratesBuy → BuyGet Alert
06/19/2024Buy Now316.14%Needham
Ami Fadia54%
$33 → $33ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now316.14%Needham
Ami Fadia54%
$33 → $33ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now404.41%HC Wainwright & Co.
Andres Maldonado45%
$50 → $40MaintainsBuyGet Alert
04/25/2024Buy Now316.14%Needham
Ami Fadia54%
$33 → $33ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now530.52%HC Wainwright & Co.
Andres Maldonado45%
$50 → $50ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now316.14%Needham
Ami Fadia54%
$30 → $33MaintainsBuyGet Alert
04/22/2024Buy Now353.97%JP Morgan
Anupam Rama59%
$32 → $36MaintainsOverweightGet Alert
03/26/2024Buy Now404.41%Piper Sandler
Joseph Catanzaro43%
$40 → $40MaintainsOverweightGet Alert
02/28/2024Buy Now404.41%Piper Sandler
Joseph Catanzaro43%
$45 → $40MaintainsOverweightGet Alert
02/27/2024Buy Now454.85%Goldman Sachs
Andrea Tan40%
$50 → $44MaintainsBuyGet Alert
02/27/2024Buy Now—Oppenheimer
Matthew Biegler37%
—ReiteratesPerform → PerformGet Alert
11/07/2023Buy Now341.36%Wedbush
Robert Driscoll45%
$39 → $35MaintainsOutperformGet Alert
11/07/2023Buy Now328.75%Needham
Ami Fadia54%
→ $34ReiteratesBuy → BuyGet Alert
09/12/2023Buy Now379.19%Wedbush
Robert Driscoll45%
→ $38ReiteratesOutperform → OutperformGet Alert
09/12/2023Buy Now328.75%Needham
Ami Fadia54%
→ $34ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now328.75%Needham
Ami Fadia54%
→ $34Reiterates → BuyGet Alert
08/08/2023Buy Now580.96%Goldman Sachs
Andrea Tan40%
$63 → $54MaintainsBuyGet Alert
08/08/2023Buy Now530.52%HC Wainwright & Co.
Andres Maldonado45%
→ $50ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now379.19%Wedbush
Robert Driscoll45%
→ $38ReiteratesOutperform → OutperformGet Alert
06/05/2023Buy Now404.41%Needham
Ami Fadia54%
→ $40ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now530.52%HC Wainwright & Co.
Andres Maldonado45%
$45 → $50MaintainsBuyGet Alert
05/18/2023Buy Now467.47%HC Wainwright & Co.
Andres Maldonado45%
→ $45ReiteratesBuy → BuyGet Alert
05/08/2023Buy Now404.41%Needham
Ami Fadia54%
$44 → $40MaintainsBuyGet Alert
05/02/2023Buy Now454.85%Needham
Ami Fadia54%
→ $44Reiterates → BuyGet Alert
04/25/2023Buy Now13.49%B of A Securities
Alec Stranahan33%
$34 → $9DowngradeBuy → UnderperformGet Alert
04/05/2023Buy Now454.85%Needham
Ami Fadia54%
$48 → $44MaintainsBuyGet Alert
03/07/2023Buy Now505.3%Needham
Ami Fadia54%
→ $48Reiterates → BuyGet Alert
03/07/2023Buy Now467.47%HC Wainwright & Co.
Andres Maldonado45%
→ $45Reiterates → BuyGet Alert
02/08/2023Buy Now404.41%Capital One
Naureen Quibria19%
→ $40Initiates → OverweightGet Alert
02/03/2023Buy Now—Oppenheimer
Matthew Biegler37%
—Initiates → PerformGet Alert
01/09/2023Buy Now681.84%Goldman Sachs
Andrea Tan40%
$45 → $62MaintainsBuyGet Alert
01/09/2023Buy Now467.47%Piper Sandler
Joseph Catanzaro43%
$40 → $45MaintainsOverweightGet Alert
01/09/2023Buy Now467.47%HC Wainwright & Co.
Andres Maldonado45%
$35 → $45MaintainsBuyGet Alert
12/15/2022Buy Now341.36%HC Wainwright & Co.
Andres Maldonado45%
→ $35Initiates → BuyGet Alert
12/14/2022Buy Now404.41%Needham
Ami Fadia54%
→ $40Initiates → BuyGet Alert
12/05/2022Buy Now467.47%Goldman Sachs
Andrea Tan40%
→ $45Initiates → BuyGet Alert
12/01/2022Buy Now328.75%B of A Securities
Alec Stranahan33%
→ $34Initiates → BuyGet Alert
06/21/2022Buy Now404.41%Piper Sandler
Joseph Catanzaro43%
$35 → $40MaintainsOverweightGet Alert
06/14/2022Buy Now341.36%Wedbush
Robert Driscoll45%
$32 → $35MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Day One Biopharmaceutical (DAWN) stock?

A

The latest price target for Day One Biopharmaceutical (NASDAQ:DAWN) was reported by HC Wainwright & Co. on April 3, 2025. The analyst firm set a price target for $36.00 expecting DAWN to rise to within 12 months (a possible 353.97% upside). 24 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?

A

The latest analyst rating for Day One Biopharmaceutical (NASDAQ:DAWN) was provided by HC Wainwright & Co., and Day One Biopharmaceutical reiterated their buy rating.

Q

When was the last upgrade for Day One Biopharmaceutical (DAWN)?

A

The last upgrade for Day One Biopharmaceuticals Inc happened on August 1, 2024 when B of A Securities raised their price target to $24. B of A Securities previously had an underperform for Day One Biopharmaceuticals Inc.

Q

When was the last downgrade for Day One Biopharmaceutical (DAWN)?

A

The last downgrade for Day One Biopharmaceuticals Inc happened on April 25, 2023 when B of A Securities changed their price target from $34 to $9 for Day One Biopharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on April 3, 2025 so you should expect the next rating to be made available sometime around April 3, 2026.

Q

Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?

A

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $36.00 to $36.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $7.93, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch